Additionally, the 36-month beta value for TOI is 0.13. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for TOI is 32.51M and currently, short sellers hold a 3.98% ratio of that float. The average trading volume of TOI on April 11, 2025 was 859.81K shares.
TOI) stock’s latest price update
The stock price of Oncology Institute Inc (NASDAQ: TOI) has jumped by 7.64 compared to previous close of 1.57. Despite this, the company has seen a gain of 17.36% in its stock price over the last five trading days. globenewswire.com reported 2025-04-09 that TORONTO, April 09, 2025 (GLOBE NEWSWIRE) — The Topicus.com Inc. (“Topicus”) (TSXV:TOI) annual general meeting of shareholders will be held on Tuesday, May 13, 2025 at 8:00 a.m. EST using a virtual meeting format with proceedings conducted solely via live audio webcast. The Lumine Group Inc. (“Lumine Group”) (TSXV:LMN) annual general meeting of shareholders will be held on Tuesday, May 13, 2025 at 8:30 a.m. EST using a virtual meeting format with proceedings conducted solely via live audio webcast. The Constellation Software Inc. (“Constellation” or “CSI”) (TSX:CSU) annual meeting of shareholders will be held on Tuesday, May 13, 2025 at 9:00 a.m. EST using a virtual meeting format, with proceedings conducted solely via live audio webcast.
TOI’s Market Performance
TOI’s stock has risen by 17.36% in the past week, with a monthly rise of 161.25% and a quarterly rise of 465.41%. The volatility ratio for the week is 23.06% while the volatility levels for the last 30 days are 21.88% for Oncology Institute Inc The simple moving average for the past 20 days is 42.26% for TOI’s stock, with a 228.46% simple moving average for the past 200 days.
Analysts’ Opinion of TOI
Many brokerage firms have already submitted their reports for TOI stocks, with Jefferies repeating the rating for TOI by listing it as a “Buy.” The predicted price for TOI in the upcoming period, according to Jefferies is $2.50 based on the research report published on February 26, 2024 of the previous year 2024.
Guggenheim, on the other hand, stated in their research note that they expect to see TOI reach a price target of $7. The rating they have provided for TOI stocks is “Buy” according to the report published on September 14th, 2022.
Jefferies gave a rating of “Buy” to TOI, setting the target price at $10 in the report published on August 15th of the previous year.
TOI Trading at 72.63% from the 50-Day Moving Average
After a stumble in the market that brought TOI to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 1.81% of gains for the given period.
Volatility was left at 21.88%, however, over the last 30 days, the volatility rate increased by 23.06%, as shares surge +160.04% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +101.19% upper at present.
During the last 5 trading sessions, TOI rose by +17.36%, which changed the moving average for the period of 200-days by +301.04% in comparison to the 20-day moving average, which settled at $1.1879. In addition, Oncology Institute Inc saw 446.93% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TOI starting from Virnich Daniel, who purchase 22,640 shares at the price of $1.04 back on Mar 26 ’25. After this action, Virnich Daniel now owns 724,363 shares of Oncology Institute Inc, valued at $23,584 using the latest closing price.
Podnos Yale, the Chief Medical Officer of Oncology Institute Inc, purchase 9,056 shares at $1.04 during a trade that took place back on Mar 26 ’25, which means that Podnos Yale is holding 79,049 shares at $9,434 based on the most recent closing price.
Stock Fundamentals for TOI
Current profitability levels for the company are sitting at:
- -0.15 for the present operating margin
- 0.13 for the gross margin
The net margin for Oncology Institute Inc stands at -0.16. The total capital return value is set at -0.5. Equity return is now at value -174.88, with -26.41 for asset returns.
Based on Oncology Institute Inc (TOI), the company’s capital structure generated 0.89 points at debt to capital in total, while cash flow to debt ratio is standing at -0.88. The debt to equity ratio resting at 8.36. The interest coverage ratio of the stock is -8.02.
Currently, EBITDA for the company is -50.88 million with net debt to EBITDA at 0.36. When we switch over and look at the enterprise to sales, we see a ratio of 0.28. The receivables turnover for the company is 8.08for trailing twelve months and the total asset turnover is 2.28. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.15.
Conclusion
In conclusion, Oncology Institute Inc (TOI) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
